Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Pachón J[au]:

Optimizing the Clinical Use of Vancomycin. Álvarez R et al. Antimicrob Agents Chemother. (2016)

Combating virulence of Gram-negative bacilli by OmpA inhibition. Vila-Farrés X et al. Sci Rep. (2017)

Peptidoglycan recycling contributes to intrinsic resistance to fosfomycin in Acinetobacter baumannii. Gil-Marqués ML et al. J Antimicrob Chemother. (2018)

Search results

Items: 1 to 50 of 268

1.

Structure-Activity Relationship Studies on Diversified Salicylamide Derivatives as Potent Inhibitors of Human Adenovirus Infection.

Xu J, Berastegui-Cabrera J, Chen H, Pachón J, Zhou J, Sánchez-Céspedes J.

J Med Chem. 2020 Mar 26;63(6):3142-3160. doi: 10.1021/acs.jmedchem.9b01950. Epub 2020 Feb 28.

PMID:
32045239
2.

T-cells immune response controls the high incidence of adenovirus infection in adult allogenic hematopoietic transplantation recipients.

Sánchez-Céspedes J, Marrugal-Lorenzo JA, Martín-Gandul C, Rodríguez-Torres N, Montero-Mateos E, Serna-Gallego A, Escamilla-Gómez V, Merino L, Espigado I, Pachón J, Pérez-Simón JA, Aguilar-Guisado M.

Haematologica. 2020 Jan 23. pii: haematol.2019.240101. doi: 10.3324/haematol.2019.240101. [Epub ahead of print] No abstract available.

3.

Influence of flow on phosphorus-dynamics and particle size in agricultural drainage ditch sediments.

Capasso J, Bhadha JH, Bacon A, Vardanyan L, Khatiwada R, Pachon J, Clark M, Lang T.

PLoS One. 2020 Jan 13;15(1):e0227489. doi: 10.1371/journal.pone.0227489. eCollection 2020.

4.

A lipopolysaccharide-free outer membrane vesicle vaccine protects against Acinetobacter baumannii infection.

Pulido MR, García-Quintanilla M, Pachón J, McConnell MJ.

Vaccine. 2020 Jan 22;38(4):719-724. doi: 10.1016/j.vaccine.2019.11.043. Epub 2019 Dec 13.

PMID:
31843268
5.

Phylogeny, Resistome, and Virulome of Escherichia coli Causing Biliary Tract Infections.

Rodríguez-Villodres Á, Bonnin RA, Ortiz de la Rosa JM, Álvarez-Marín R, Naas T, Aznar J, Pachón J, Lepe JA, Smani Y.

J Clin Med. 2019 Dec 2;8(12). pii: E2118. doi: 10.3390/jcm8122118.

6.

Combined Use of the Ab105-2φΔCI Lytic Mutant Phage and Different Antibiotics in Clinical Isolates of Multi-Resistant Acinetobacter baumannii.

Blasco L, Ambroa A, Lopez M, Fernandez-Garcia L, Bleriot I, Trastoy R, Ramos-Vivas J, Coenye T, Fernandez-Cuenca F, Vila J, Martinez-Martinez L, Rodriguez-Baño J, Pascual A, Cisneros JM, Pachon J, Bou G, Tomas M.

Microorganisms. 2019 Nov 12;7(11). pii: E556. doi: 10.3390/microorganisms7110556.

7.

Optimization of piperazine-derived ureas privileged structures for effective antiadenovirus agents.

Mazzotta S, Marrugal-Lorenzo JA, Vega-Holm M, Serna-Gallego A, Álvarez-Vidal J, Berastegui-Cabrera J, Pérez Del Palacio J, Díaz C, Aiello F, Pachón J, Iglesias-Guerra F, Vega-Pérez JM, Sánchez-Céspedes J.

Eur J Med Chem. 2020 Jan 1;185:111840. doi: 10.1016/j.ejmech.2019.111840. Epub 2019 Nov 3.

PMID:
31711794
8.

Pangenome of Acinetobacter baumannii uncovers two groups of genomes, one of them with genes involved in CRISPR/Cas defence systems associated with the absence of plasmids and exclusive genes for biofilm formation.

Mangas EL, Rubio A, Álvarez-Marín R, Labrador-Herrera G, Pachón J, Pachón-Ibáñez ME, Divina F, Pérez-Pulido AJ.

Microb Genom. 2019 Nov;5(11). doi: 10.1099/mgen.0.000309.

9.

Extended-spectrum resistance to β-lactams/β-lactamase inhibitors (ESRI) evolved from low-level resistant Escherichia coli.

Rodríguez-Villodres Á, Gil-Marqués ML, Álvarez-Marín R, Bonnin RA, Pachón-Ibáñez ME, Aguilar-Guisado M, Naas T, Aznar J, Pachón J, Lepe JA, Smani Y.

J Antimicrob Chemother. 2020 Jan 1;75(1):77-85. doi: 10.1093/jac/dkz393.

PMID:
31613964
10.

Prevalence and clinical impact of Streptococcus pneumoniae nasopharyngeal carriage in solid organ transplant recipients.

Roca-Oporto C, Cebrero-Cangueiro T, Gil-Marqués ML, Labrador-Herrera G, Smani Y, González-Roncero FM, Marín LM, Pachón J, Pachón-Ibáñez ME, Cordero E.

BMC Infect Dis. 2019 Aug 6;19(1):697. doi: 10.1186/s12879-019-4321-8.

11.

The anthelmintic oxyclozanide restores the activity of colistin against colistin-resistant Gram-negative bacilli.

Ayerbe-Algaba R, Gil-Marqués ML, Miró-Canturri A, Parra-Millán R, Pachón-Ibáñez ME, Jiménez-Mejías ME, Pachón J, Smani Y.

Int J Antimicrob Agents. 2019 Oct;54(4):507-512. doi: 10.1016/j.ijantimicag.2019.07.006. Epub 2019 Jul 9.

PMID:
31299296
12.

Relationship Between Different Resistance Mechanisms and Virulence in Acinetobacter baumannii.

Espinal P, Pantel A, Rolo D, Marti S, López-Rojas R, Smani Y, Pachón J, Vila J, Lavigne JP.

Microb Drug Resist. 2019 Jun;25(5):752-760. doi: 10.1089/mdr.2018.0182. Epub 2019 Jan 11.

PMID:
30632884
13.

Repositioning salicylanilide anthelmintic drugs to treat adenovirus infections.

Marrugal-Lorenzo JA, Serna-Gallego A, Berastegui-Cabrera J, Pachón J, Sánchez-Céspedes J.

Sci Rep. 2019 Jan 9;9(1):17. doi: 10.1038/s41598-018-37290-3.

14.

Relationship Between the Quorum Network (Sensing/Quenching) and Clinical Features of Pneumonia and Bacteraemia Caused by A. baumannii.

Fernandez-Garcia L, Ambroa A, Blasco L, Bleriot I, López M, Alvarez-Marin R, Fernández-Cuenca F, Martinez-Martinez L, Vila J, Rodríguez-Baño J, Garnacho-Montero J, Cisneros JM, Pascual A, Pachón J, Bou G, Smani Y, Tomás M.

Front Microbiol. 2018 Dec 17;9:3105. doi: 10.3389/fmicb.2018.03105. eCollection 2018.

15.

In vitro Activity of Pentamidine Alone and in Combination With Aminoglycosides, Tigecycline, Rifampicin, and Doripenem Against Clinical Strains of Carbapenemase-Producing and/or Colistin-Resistant Enterobacteriaceae.

Cebrero-Cangueiro T, Álvarez-Marín R, Labrador-Herrera G, Smani Y, Cordero-Matía E, Pachón J, Pachón-Ibáñez ME.

Front Cell Infect Microbiol. 2018 Oct 18;8:363. doi: 10.3389/fcimb.2018.00363. eCollection 2018.

16.

Synergistic Activity of Niclosamide in Combination With Colistin Against Colistin-Susceptible and Colistin-Resistant Acinetobacter baumannii and Klebsiella pneumoniae.

Ayerbe-Algaba R, Gil-Marqués ML, Jiménez-Mejías ME, Sánchez-Encinales V, Parra-Millán R, Pachón-Ibáñez ME, Pachón J, Smani Y.

Front Cell Infect Microbiol. 2018 Oct 3;8:348. doi: 10.3389/fcimb.2018.00348. eCollection 2018.

17.

Inhibition of adenovirus infection by mifepristone.

Marrugal-Lorenzo JA, Serna-Gallego A, González-González L, Buñuales M, Poutou J, Pachón J, Gonzalez-Aparicio M, Hernandez-Alcoceba R, Sánchez-Céspedes J.

Antiviral Res. 2018 Nov;159:77-83. doi: 10.1016/j.antiviral.2018.09.011. Epub 2018 Sep 27.

PMID:
30268911
18.

Synergistic activity of an OmpA inhibitor and colistin against colistin-resistant Acinetobacter baumannii: mechanistic analysis and in vivo efficacy.

Parra-Millán R, Vila-Farrés X, Ayerbe-Algaba R, Varese M, Sánchez-Encinales V, Bayó N, Pachón-Ibáñez ME, Teixidó M, Vila J, Pachón J, Giralt E, Smani Y.

J Antimicrob Chemother. 2018 Dec 1;73(12):3405-3412. doi: 10.1093/jac/dky343.

PMID:
30188994
19.

Peptidoglycan recycling contributes to intrinsic resistance to fosfomycin in Acinetobacter baumannii.

Gil-Marqués ML, Moreno-Martínez P, Costas C, Pachón J, Blázquez J, McConnell MJ.

J Antimicrob Chemother. 2018 Nov 1;73(11):2960-2968. doi: 10.1093/jac/dky289.

PMID:
30124902
20.

Effect of Hypoxia on the Pathogenesis of Acinetobacter baumannii and Pseudomonas aeruginosa In Vitro and in Murine Experimental Models of Infection.

Gil-Marqués ML, Pachón-Ibáñez ME, Pachón J, Smani Y.

Infect Immun. 2018 Sep 21;86(10). pii: e00543-18. doi: 10.1128/IAI.00543-18. Print 2018 Oct.

21.

Multiple Multicomponent Reactions: Unexplored Substrates, Selective Processes, and Versatile Chemotypes in Biomedicine.

Ghashghaei O, Caputo S, Sintes M, Revés M, Kielland N, Estarellas C, Luque FJ, Aviñó A, Eritja R, Serna-Gallego A, Marrugal-Lorenzo JA, Pachón J, Sánchez-Céspedes J, Treadwell R, de Moliner F, Vendrell M, Lavilla R.

Chemistry. 2018 Sep 25;24(54):14513-14521. doi: 10.1002/chem.201802877. Epub 2018 Aug 28.

PMID:
29974986
22.

Immunization with lipopolysaccharide-free outer membrane complexes protects against Acinetobacter baumannii infection.

Pulido MR, García-Quintanilla M, Pachón J, McConnell MJ.

Vaccine. 2018 Jul 5;36(29):4153-4156. doi: 10.1016/j.vaccine.2018.05.113. Epub 2018 Jun 7.

PMID:
29887323
23.

Efficacy of Colistin and Its Combination With Rifampin in Vitro and in Experimental Models of Infection Caused by Carbapenemase-Producing Clinical Isolates of Klebsiella pneumoniae.

Pachón-Ibáñez ME, Labrador-Herrera G, Cebrero-Cangueiro T, Díaz C, Smani Y, Del Palacio JP, Rodríguez-Baño J, Pascual A, Pachón J, Conejo MC.

Front Microbiol. 2018 May 15;9:912. doi: 10.3389/fmicb.2018.00912. eCollection 2018.

24.

Phenotypic changes associated with Colistin resistance due to Lipopolysaccharide loss in Acinetobacter baumannii.

Carretero-Ledesma M, García-Quintanilla M, Martín-Peña R, Pulido MR, Pachón J, McConnell MJ.

Virulence. 2018 Dec 31;9(1):930-942. doi: 10.1080/21505594.2018.1460187.

25.

Intracellular Trafficking and Persistence of Acinetobacter baumannii Requires Transcription Factor EB.

Parra-Millán R, Guerrero-Gómez D, Ayerbe-Algaba R, Pachón-Ibáñez ME, Miranda-Vizuete A, Pachón J, Smani Y.

mSphere. 2018 Mar 28;3(2). pii: e00106-18. doi: 10.1128/mSphere.00106-18. eCollection 2018 Mar-Apr.

26.

Combating virulence of Gram-negative bacilli by OmpA inhibition.

Vila-Farrés X, Parra-Millán R, Sánchez-Encinales V, Varese M, Ayerbe-Algaba R, Bayó N, Guardiola S, Pachón-Ibáñez ME, Kotev M, García J, Teixidó M, Vila J, Pachón J, Giralt E, Smani Y.

Sci Rep. 2017 Oct 31;7(1):14683. doi: 10.1038/s41598-017-14972-y.

27.

Erratum for Martínez-Florensa et al., "Protective Effects of Human and Mouse Soluble Scavenger-Like CD6 Lymphocyte Receptor in a Lethal Model of Polymicrobial Sepsis".

Martínez-Florensa M, Consuegra-Fernández M, Aranda F, Armiger-Borràs N, Di Scala M, Carrasco E, Pachón J, Vila J, González-Aseguinolaza G, Lozano F.

Antimicrob Agents Chemother. 2017 Oct 24;61(11). pii: e01997-17. doi: 10.1128/AAC.01997-17. Print 2017 Nov. No abstract available.

28.

Heteroresistance to Piperacillin-Tazobactam in Clinical Isolates of Escherichia coli Sequence Type 131.

Rodríguez-Villodres Á, Ortiz de la Rosa JM, Álvarez-Marín R, Pachón J, Aznar J, Lepe JA, Smani Y.

Antimicrob Agents Chemother. 2017 Dec 21;62(1). pii: e01923-17. doi: 10.1128/AAC.01923-17. Print 2018 Jan. No abstract available.

29.

Perspectives for clinical use of engineered human host defense antimicrobial peptides.

Pachón-Ibáñez ME, Smani Y, Pachón J, Sánchez-Céspedes J.

FEMS Microbiol Rev. 2017 May 1;41(3):323-342. doi: 10.1093/femsre/fux012. Review.

30.

Overproduction of Outer Membrane Protein A by Acinetobacter baumannii as a Risk Factor for Nosocomial Pneumonia, Bacteremia, and Mortality Rate Increase.

Sánchez-Encinales V, Álvarez-Marín R, Pachón-Ibáñez ME, Fernández-Cuenca F, Pascual A, Garnacho-Montero J, Martínez-Martínez L, Vila J, Tomás MM, Cisneros JM, Bou G, Rodríguez-Baño J, Pachón J, Smani Y.

J Infect Dis. 2017 Mar 15;215(6):966-974. doi: 10.1093/infdis/jix010.

PMID:
28453834
31.

Pathogenic Acinetobacter species have a functional type I secretion system and contact-dependent inhibition systems.

Harding CM, Pulido MR, Di Venanzio G, Kinsella RL, Webb AI, Scott NE, Pachón J, Feldman MF.

J Biol Chem. 2017 Jun 2;292(22):9075-9087. doi: 10.1074/jbc.M117.781575. Epub 2017 Apr 3.

32.

Efficacy of ceftaroline versus vancomycin in an experimental foreign-body and systemic infection model caused by biofilm-producing methicillin-resistant Staphylococcus epidermidis.

Domínguez-Herrera J, López-Rojas R, Smani Y, Labrador-Herrera G, Pachón J.

Int J Antimicrob Agents. 2016 Dec;48(6):661-665. doi: 10.1016/j.ijantimicag.2016.09.011. Epub 2016 Oct 18.

PMID:
28128094
33.

Colistin Dosage without Loading Dose Is Efficacious when Treating Carbapenem-Resistant Acinetobacter baumannii Ventilator-Associated Pneumonia Caused by Strains with High Susceptibility to Colistin.

Álvarez-Marín R, López-Rojas R, Márquez JA, Gómez MJ, Molina J, Cisneros JM, Ortiz-Leyba C, Aznar J, Garnacho-Montero J, Pachón J.

PLoS One. 2016 Dec 19;11(12):e0168468. doi: 10.1371/journal.pone.0168468. eCollection 2016.

34.

Protective Effects of Human and Mouse Soluble Scavenger-Like CD6 Lymphocyte Receptor in a Lethal Model of Polymicrobial Sepsis.

Martínez-Florensa M, Consuegra-Fernández M, Aranda F, Armiger-Borràs N, Di Scala M, Carrasco E, Pachón J, Vila J, González-Aseguinolaza G, Lozano F.

Antimicrob Agents Chemother. 2016 Dec 27;61(1). pii: e01391-16. doi: 10.1128/AAC.01391-16. Print 2017 Jan. Erratum in: Antimicrob Agents Chemother. 2017 Oct 24;61(11):.

35.

Genomic Evolution of Two Acinetobacter baumannii Clinical Strains from ST-2 Clones Isolated in 2000 and 2010 (ST-2_clon_2000 and ST-2_clon_2010).

López M, Rueda A, Florido JP, Blasco L, Gato E, Fernández-García L, Martínez-Martínez L, Fernández-Cuenca F, Pachón J, Cisneros JM, Garnacho-Montero J, Vila J, Rodríguez-Baño J, Pascual A, Bou G, Tomás M.

Genome Announc. 2016 Oct 20;4(5). pii: e01182-16. doi: 10.1128/genomeA.01182-16.

36.

Inhibition of LpxC Increases Antibiotic Susceptibility in Acinetobacter baumannii.

García-Quintanilla M, Caro-Vega JM, Pulido MR, Moreno-Martínez P, Pachón J, McConnell MJ.

Antimicrob Agents Chemother. 2016 Jul 22;60(8):5076-9. doi: 10.1128/AAC.00407-16. Print 2016 Aug.

37.

New 4-Acyl-1-phenylaminocarbonyl-2-phenylpiperazine Derivatives as Potential Inhibitors of Adenovirus Infection. Synthesis, Biological Evaluation, and Structure-activity Relationships.

Sánchez-Céspedes J, Martínez-Aguado P, Vega-Holm M, Serna-Gallego A, Candela JI, Marrugal-Lorenzo JA, Pachón J, Iglesias-Guerra F, Vega-Pérez JM.

J Med Chem. 2016 Jun 9;59(11):5432-48. doi: 10.1021/acs.jmedchem.6b00300. Epub 2016 May 31.

PMID:
27195951
38.

Impaired growth under iron-limiting conditions associated with the acquisition of colistin resistance in Acinetobacter baumannii.

López-Rojas R, García-Quintanilla M, Labrador-Herrera G, Pachón J, McConnell MJ.

Int J Antimicrob Agents. 2016 Jun;47(6):473-7. doi: 10.1016/j.ijantimicag.2016.03.010. Epub 2016 Apr 22.

PMID:
27179817
39.

Phosphorylation of gH2AX as a novel prognostic biomarker for laryngoesophageal dysfunction-free survival.

de Miguel-Luken MJ, Chaves-Conde M, Quintana B, Menoyo A, Tirado I, de Miguel-Luken V, Pachón J, Chinchón D, Suarez V, Carnero A.

Oncotarget. 2016 May 31;7(22):31723-37. doi: 10.18632/oncotarget.9172.

40.

Efficacy of Lysophosphatidylcholine in Combination with Antimicrobial Agents against Acinetobacter baumannii in Experimental Murine Peritoneal Sepsis and Pneumonia Models.

Parra Millán R, Jiménez Mejías ME, Sánchez Encinales V, Ayerbe Algaba R, Gutiérrez Valencia A, Pachón Ibáñez ME, Díaz C, Pérez Del Palacio J, López Cortés LF, Pachón J, Smani Y.

Antimicrob Agents Chemother. 2016 Jul 22;60(8):4464-70. doi: 10.1128/AAC.02708-15. Print 2016 Aug.

41.

New molecules and adjuvants in the treatment of infections by Acinetobacter baumannii.

Smani Y, Pachón-Ibáñez ME, Pachón J.

Expert Opin Pharmacother. 2016 Jun;17(9):1207-14. doi: 10.1080/14656566.2016.1176144. Epub 2016 Apr 28. Review.

PMID:
27067283
42.

Draft Genome Sequences of Seven Multidrug-Resistant Acinetobacter baumannii Strains, Isolated from Respiratory Samples in Spain.

Labrador-Herrera G, Álvarez R, López-Rojas R, Smani Y, Cebrero-Cangueiro T, Rueda A, Pérez Florido J, Pachón J, Pachón-Ibáñez ME.

Genome Announc. 2016 Mar 31;4(2). pii: e00083-16. doi: 10.1128/genomeA.00083-16.

43.

Optimizing the Clinical Use of Vancomycin.

Álvarez R, López Cortés LE, Molina J, Cisneros JM, Pachón J.

Antimicrob Agents Chemother. 2016 Apr 22;60(5):2601-9. doi: 10.1128/AAC.03147-14. Print 2016 May. Review.

44.

Use of adjuvants in the treatment of Acinetobacter baumannii.

Pachón-Ibáñez ME, Smani Y, Pachón J.

Expert Rev Anti Infect Ther. 2016;14(2):153-5. doi: 10.1586/14787210.2016.1126508. Epub 2015 Dec 19.

PMID:
26620637
45.

Reduced susceptibility to biocides in Acinetobacter baumannii: association with resistance to antimicrobials, epidemiological behaviour, biological cost and effect on the expression of genes encoding porins and efflux pumps.

Fernández-Cuenca F, Tomás M, Caballero-Moyano FJ, Bou G, Martínez-Martínez L, Vila J, Pachón J, Cisneros JM, Rodríguez-Baño J, Pascual Á; Spanish Group of Nosocomial Infections (GEIH) from the Spanish Society of Clinical Microbiology and Infectious Diseases (SEIMC) and the Spanish Network for Research in Infectious Diseases (REIPI); Spanish Group of Nosocomial Infections GEIH from the Spanish Society of Clinical Microbiology and Infectious Diseases SEIMC and the Spanish Network for Research in Infectious Diseases REIPI.

J Antimicrob Chemother. 2015 Dec;70(12):3222-9. doi: 10.1093/jac/dkv262. Epub 2015 Sep 10.

PMID:
26517560
46.

Lipopolysaccharide loss produces partial colistin dependence and collateral sensitivity to azithromycin, rifampicin and vancomycin in Acinetobacter baumannii.

García-Quintanilla M, Carretero-Ledesma M, Moreno-Martínez P, Martín-Peña R, Pachón J, McConnell MJ.

Int J Antimicrob Agents. 2015 Dec;46(6):696-702. doi: 10.1016/j.ijantimicag.2015.07.017. Epub 2015 Sep 7.

PMID:
26391380
47.

Chronotropic incompetence in Chagas disease: usefulness of dual sensor pacemaker based on volume minute and accelerometer.

Pachón JC.

Rev Bras Cir Cardiovasc. 2015 Jul-Sep;30(3):III-VI. doi: 10.5935/1678-9741.20150011. No abstract available.

48.

Sequence-activity relationship, and mechanism of action of mastoparan analogues against extended-drug resistant Acinetobacter baumannii.

Vila-Farrés X, López-Rojas R, Pachón-Ibáñez ME, Teixidó M, Pachón J, Vila J, Giralt E.

Eur J Med Chem. 2015 Aug 28;101:34-40. doi: 10.1016/j.ejmech.2015.06.016. Epub 2015 Jun 9.

49.

Therapeutic efficacy of lysophosphatidylcholine in severe infections caused by Acinetobacter baumannii.

Smani Y, Domínguez-Herrera J, Ibáñez-Martínez J, Pachón J.

Antimicrob Agents Chemother. 2015 Jul;59(7):3920-4. doi: 10.1128/AAC.04986-14. Epub 2015 Apr 20.

50.

MAP17 (PDZKIP1) as a novel prognostic biomarker for laryngeal cancer.

de Miguel-Luken MJ, Chaves-Conde M, de Miguel-Luken V, Muñoz-Galván S, López-Guerra JL, Mateos JC, Pachón J, Chinchón D, Suarez V, Carnero A.

Oncotarget. 2015 May 20;6(14):12625-36.

Supplemental Content

Loading ...
Support Center